Abstract: A wader has a body having a chest portion and a lower portion including two leg portions and two boots. The chest portion has first, second, third, and fourth outer pockets. Each of the first and fourth outer pockets has an opening on a side of the wader, while each of the second and third outer pockets has an opening near a midline of the wader. The chest portion has first and second interior pockets, each of which has an opening on an upper side of the pocket. The first interior pocket is adjacent the first outer pocket and inward of the first and second outer pockets; the second interior pocket is adjacent the fourth outer pocket and inward of the third and fourth outer pockets. The first interior pocket is shallower than the second outer pocket and the second interior pocket is shallower than the fourth outer pocket.

Abstract: The present invention relates to an intranasal pharmaceutical dosage form comprising a dosing unit comprising naloxone or a pharmaceutically acceptable salt thereof in an amount of equivalent to ?0.5 mg naloxone HCl dissolved in an application fluid of a volume of ?250 ?l. Furthermore, the present invention relates to such an intranasal pharmaceutical dosage form for use in the treatment of opioid overdosing and/or at least one symptom thereof.

Abstract: The present invention relates to an intranasal pharmaceutical dosage form comprising a dosing unit comprising naloxone or a pharmaceutically acceptable salt thereof in an amount of equivalent to ?0.5 mg naloxone HCl dissolved in an application fluid of a volume of ?250 ?l. Furthermore, the present invention relates to such an intranasal pharmaceutical dosage form for use in the treatment of opioid overdosing and/or at least one symptom thereof.

Abstract: A wader has a body having a chest portion and a lower portion including two leg portions and two boots. The chest portion has first, second, third, and fourth outer pockets. Each of the first and fourth outer pockets has an opening on a side of the wader, while each of the second and third outer pockets has an opening near a midline of the wader. The chest portion has first and second interior pockets, each of which has an opening on an upper side of the pocket. The first interior pocket is adjacent the first outer pocket and inward of the first and second outer pockets; the second interior pocket is adjacent the fourth outer pocket and inward of the third and fourth outer pockets. The first interior pocket is shallower than the second outer pocket and the second interior pocket is shallower than the fourth outer pocket.

Abstract: The present invention relates to an intranasal pharmaceutical dosage form comprising a dosing unit comprising naloxone or a pharmaceutically acceptable salt thereof in an amount of equivalent to ?0.5 mg naloxone HCl dissolved in an application fluid of a volume of ?250 ?l. Furthermore, the present invention relates to such an intranasal pharmaceutical dosage form for use in the treatment of opioid overdosing and/or at least one symptom thereof.

Abstract: The present invention relates to an intranasal pharmaceutical dosage form comprising a dosing unit comprising naloxone or a pharmaceutically acceptable salt thereof in an amount of equivalent to ?0.5 mg naloxone HC dissolved in an application fluid of a volume of ?250 ?l. Furthermore, the present invention relates to such an intranasal pharmaceutical dosage form for use in the treatment of opioid overdosing and/or at least one symptom thereof.

Abstract: The present invention relates to an intranasal pharmaceutical dosage form comprising a dosing unit comprising naloxone or a pharmaceutically acceptable salt thereof in an amount of equivalent to ?0.5 mg naloxone HC dissolved in an application fluid of a volume of ?250 ?l. Furthermore, the present invention relates to such an intranasal pharmaceutical dosage form for use in the treatment of opioid overdosing and/or at least one symptom thereof.

Abstract: The present invention relates to an intranasal pharmaceutical dosage form comprising a dosing unit comprising naloxone or a pharmaceutically acceptable salt thereof in an amount of equivalent to ?0.5 mg naloxone HCl dissolved in an application fluid of a volume of ?250 ?l. Furthermore, the present invention relates to such an intranasal pharmaceutical dosage form for use in the treatment of opioid overdosing and/or at least one symptom thereof.

Abstract: The present invention relates to an intranasal pharmaceutical dosage form comprising a dosing unit comprising naloxone or a pharmaceutically acceptable salt thereof in an amount of equivalent to ?0.5 mg naloxone HCl dissolved in an application fluid of a volume of ?250 ?l. Furthermore, the present invention relates to such an intranasal pharmaceutical dosage form for use in the treatment of opioid overdosing and/or at least one symptom thereof.

Abstract: The present invention relates to an intranasal pharmaceutical dosage form comprising a dosing unit comprising naloxone or a pharmaceutically acceptable salt thereof in an amount of equivalent to ?0.5 mg naloxone HCl dissolved in an application fluid of a volume of ?250 ?l. Furthermore, the present invention relates to such an intranasal pharmaceutical dosage form for use in the treatment of opioid overdosing and/or at least one symptom thereof.

Abstract: The present invention relates to an intranasal pharmaceutical dosage form comprising a dosing unit comprising naloxone or a pharmaceutically acceptable salt thereof in an amount of equivalent to ?0.5 mg naloxone HCl dissolved in an application fluid of a volume of ?250 ?l. Furthermore, the present invention relates to such an intranasal pharmaceutical dosage form for use in the treatment of opioid overdosing and/or at least one symptom thereof.

Abstract: A system and method for hardware error reporting and recovery is presented. An operating system provides an error signal handler, a platform-independent error processing module, and a platform-specific error handler. The error signal handler is configured to detect the occurrence of a hardware error and to notify the platform-independent error processing module of the detected hardware error. The platform-independent error processing module is configured to process the hardware error detected by the error signal handler. The platform-specific error handler is configured to perform platform-specific error processing of the hardware error in cooperation with the platform-independent error processing module.